142 related articles for article (PubMed ID: 33374770)
1. SATB1-Mediated Upregulation of the Oncogenic Receptor Tyrosine Kinase HER3 Antagonizes MET Inhibition in Gastric Cancer Cells.
Jenke R; Holzhäuser-Rein M; Mueller-Wilke S; Lordick F; Aigner A; Büch T
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374770
[TBL] [Abstract][Full Text] [Related]
2. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells.
Bachleitner-Hofmann T; Sun MY; Chen CT; Tang L; Song L; Zeng Z; Shah M; Christensen JG; Rosen N; Solit DB; Weiser MR
Mol Cancer Ther; 2008 Nov; 7(11):3499-508. PubMed ID: 18974395
[TBL] [Abstract][Full Text] [Related]
3. SATB1 as oncogenic driver and potential therapeutic target in head & neck squamous cell carcinoma (HNSCC).
Panchal O; Wichmann G; Grenman R; Eckhardt L; Kunz-Schughart LA; Franke H; Dietz A; Aigner A
Sci Rep; 2020 May; 10(1):8615. PubMed ID: 32451408
[TBL] [Abstract][Full Text] [Related]
4. Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks.
Kataoka Y; Mukohara T; Tomioka H; Funakoshi Y; Kiyota N; Fujiwara Y; Yashiro M; Hirakawa K; Hirai M; Minami H
Invest New Drugs; 2012 Aug; 30(4):1352-60. PubMed ID: 21655918
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of HER Receptors Reveals Distinct Mechanisms of Compensatory Upregulation of Other HER Family Members: Basis for Acquired Resistance and for Combination Therapy.
Gutsch D; Jenke R; Büch T; Aigner A
Cells; 2021 Jan; 10(2):. PubMed ID: 33572976
[TBL] [Abstract][Full Text] [Related]
6. Met-HER3 crosstalk supports proliferation via MPZL3 in MET-amplified cancer cells.
Stern YE; Al-Ghabkari A; Monast A; Fiset B; Aboualizadeh F; Yao Z; Stagljar I; Walsh LA; Duhamel S; Park M
Cell Mol Life Sci; 2022 Mar; 79(3):178. PubMed ID: 35249128
[TBL] [Abstract][Full Text] [Related]
7. Essential role of Her3 in two signaling transduction patterns: Her2/Her3 and MET/Her3 in proliferation of human gastric cancer.
Yun C; Gang L; Rongmin G; Xu W; Xuezhi M; Huanqiu C
Mol Carcinog; 2015 Dec; 54(12):1700-9. PubMed ID: 25400108
[TBL] [Abstract][Full Text] [Related]
8. The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma.
Steinway SN; Dang H; You H; Rountree CB; Ding W
PLoS One; 2015; 10(5):e0128159. PubMed ID: 26000702
[TBL] [Abstract][Full Text] [Related]
9. Effects of silibinin on growth and invasive properties of human ovarian carcinoma cells through suppression of heregulin/HER3 pathway.
Momeny M; Ghasemi R; Valenti G; Miranda M; Zekri A; Zarrinrad G; Javadikooshesh S; Yaghmaie M; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Tumour Biol; 2016 Mar; 37(3):3913-23. PubMed ID: 26482609
[TBL] [Abstract][Full Text] [Related]
10. Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway.
Sakai K; Yokote H; Murakami-Murofushi K; Tamura T; Saijo N; Nishio K
Cancer Sci; 2007 Sep; 98(9):1498-503. PubMed ID: 17627612
[TBL] [Abstract][Full Text] [Related]
11. MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer.
Novoplansky O; Fury M; Prasad M; Yegodayev K; Zorea J; Cohen L; Pelossof R; Cohen L; Katabi N; Cecchi F; Joshua BZ; Popovtzer A; Baselga J; Scaltriti M; Elkabets M
Int J Cancer; 2019 Aug; 145(3):748-762. PubMed ID: 30694565
[TBL] [Abstract][Full Text] [Related]
12. 4-Phenybutyric acid promotes gastric cancer cell migration via histone deacetylase inhibition-mediated HER3/HER4 up-regulation.
Shi X; Zheng C; Li C; Hou K; Wang X; Yang Z; Liu C; Liu Y; Che X; Qu X
Cell Biol Int; 2018 Jan; 42(1):53-62. PubMed ID: 28851073
[TBL] [Abstract][Full Text] [Related]
13. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
[TBL] [Abstract][Full Text] [Related]
14. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
Kim J; Lee J; Kim C; Choi J; Kim A
Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
[TBL] [Abstract][Full Text] [Related]
15. Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition.
Corso S; Ghiso E; Cepero V; Sierra JR; Migliore C; Bertotti A; Trusolino L; Comoglio PM; Giordano S
Mol Cancer; 2010 May; 9():121. PubMed ID: 20500904
[TBL] [Abstract][Full Text] [Related]
16. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L
Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355
[TBL] [Abstract][Full Text] [Related]
17. Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer.
Zhang Z; Wang J; Ji D; Wang C; Liu R; Wu Z; Liu L; Zhu D; Chang J; Geng R; Xiong L; Fang Q; Li J
Clin Cancer Res; 2014 Sep; 20(17):4559-73. PubMed ID: 24973425
[TBL] [Abstract][Full Text] [Related]
18. Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification.
Okamoto W; Okamoto I; Arao T; Kuwata K; Hatashita E; Yamaguchi H; Sakai K; Yanagihara K; Nishio K; Nakagawa K
Mol Cancer Ther; 2012 Jul; 11(7):1557-64. PubMed ID: 22729845
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Src impairs the growth of met-addicted gastric tumors.
Bertotti A; Bracco C; Girolami F; Torti D; Gastaldi S; Galimi F; Medico E; Elvin P; Comoglio PM; Trusolino L
Clin Cancer Res; 2010 Aug; 16(15):3933-43. PubMed ID: 20628031
[TBL] [Abstract][Full Text] [Related]
20. Dynamic reprogramming of signaling upon met inhibition reveals a mechanism of drug resistance in gastric cancer.
Lai AZ; Cory S; Zhao H; Gigoux M; Monast A; Guiot MC; Huang S; Tofigh A; Thompson C; Naujokas M; Marcus VA; Bertos N; Sehat B; Perera RM; Bell ES; Page BD; Gunning PT; Ferri LE; Hallett M; Park M
Sci Signal; 2014 Apr; 7(322):ra38. PubMed ID: 24757178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
